Report dose-to-medium in clinical trials where available; a consensus from the Global Harmonisation Group to maximize consistency

Stephen F. Kry, Jessica Lye, Catharine H. Clark, Nicolaus Andratschke, Alexis Dimitriadis, David Followill, Rebecca Howell, Mohammad Hussein, Masayori Ishikawa, Satoshi Kito, Tomas Kron, Jonny Lee, Jeff Michalski, Angelo Filippo Monti, Nick Reynaert, Paige Taylor, Karen Venables, Ying Xiao, Joerg Lehmann

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations

Abstract

Purpose: To promote consistency in clinical trials by recommending a uniform framework as it relates to radiation transport and dose calculation in water versus in medium. Methods: The Global Quality Assurance of Radiation Therapy Clinical Trials Harmonisation Group (GHG; www.rtqaharmonization.org) compared the differences between dose to water in water (Dw,w), dose to water in medium (Dw,m), and dose to medium in medium (Dm,m). This was done based on a review of historical frameworks, existing literature and standards, clinical issues in the context of clinical trials, and the trajectory of radiation dose calculations. Based on these factors, recommendations were developed. Results: No framework was found to be ideal or perfect given the history, complexity, and current status of radiation therapy. Nevertheless, based on the evidence available, the GHG established a recommendation preferring dose to medium in medium (Dm,m). Conclusions: Dose to medium in medium (Dm,m) is the preferred dose calculation and reporting framework. If an institution's planning system can only calculate dose to water in water (Dw,w), this is acceptable.

Original languageEnglish (US)
Pages (from-to)106-111
Number of pages6
JournalRadiotherapy and Oncology
Volume159
DOIs
StatePublished - Jun 2021

Keywords

  • Clinical trial
  • Dose calculation
  • Dose to medium, Dose to water
  • GHG
  • Radiation dosage

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Report dose-to-medium in clinical trials where available; a consensus from the Global Harmonisation Group to maximize consistency'. Together they form a unique fingerprint.

Cite this